期刊
CIRCULATION RESEARCH
卷 129, 期 1, 页码 155-173出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCRESAHA.121.318145
关键词
endothelium; mutation; precision medicine; sirolimus; thalidomide
资金
- Fonds de la Recherche Scientifique-FNRS grant [T.0247.19, T.0146.16]
- Fund Generet [2018-J1810250-211305]
- la Region wallonne dans le cadre du financement de l'axe strategique FRFS-WELBIO [WELBIO-CR-2019C-06]
- Lymphatic malformation Institute (LMI)
In recent years, research on genetic and somatic mutations in vascular and lymphatic malformations has led to the evaluation of preexisting cancer drugs that interfere with these signaling pathways, marking the beginning of personalized treatment for vascular anomalies.
Vascular and lymphatic malformations represent a challenge for clinicians. The identification of inherited and somatic mutations in important signaling pathways, including the PI3K (phosphoinositide 3-kinase)/AKT (protein kinase B)/mTOR (mammalian target of rapamycin), RAS (rat sarcoma)/RAF (rapidly accelerated fibrosarcoma)/MEK (mitogen-activated protein kinase kinase)/ERK (extracellular signal-regulated kinases), HGF (hepatocyte growth factor)/c-Met (hepatocyte growth factor receptor), and VEGF (vascular endothelial growth factor) A/VEGFR (vascular endothelial growth factor receptor) 2 cascades has led to the evaluation of tailored strategies with preexisting cancer drugs that interfere with these signaling pathways. The era of theranostics has started for the treatment of vascular anomalies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据